Puneet Masson, MD is a reproductive urologist who earned his MD from Columbia University College of Physicians and Surgeons. He completed a six-year urology residency at New York Presbyterian Hospital – Weill Cornell Medical College, followed by an Andrology and Male Fertility fellowship at Northwestern University Feinberg School of Medicine.

Dr. Masson serves as Associate Professor and Director of Reproductive Urology at the University of Miami / Desai Sethi Urology Institute. Previously, Dr. Masson was the Regional Medical Director and VP of Clinical Engagement at Posterity Health, which is network of reproductive urologists throughout the US. Prior to Posterity Health, Dr. Masson was an Associate Professor of Clinical Urology and the Director of Male Reproductive Medicine and Surgery at Penn Medicine in Philadelphia, PA. In that role, he was in an academic-oriented practice for 10 years with a joint appointment with Urology and Reproductive Endocrinology (REI).

Dr. Masson is passionate about a comprehensive, integrated approach to male factor infertility with close collaboration with REI. He developed the male fertility program at Penn Medicine as part of the combined Penn Fertility Care experience, which was caring for approximately 500 male fertility patients annually under his expertise. Dr. Masson has presented extensively on the clinical value of an integrated clinic with REI at the American Society of Reproductive Medicine (ASRM) and American Urological Association (AUA) national meetings. He also established the fertility preservation program at Penn Medicine for oncology inpatients and outpatients as well as transgender patients interested in future fertility.

“I am passionate about offering integrated, comprehensive care for couples presenting with infertility. Though the cornerstone of male fertility testing, a semen analysis has limitations in fully evaluating the male partner. I became an advisor for Inherent Bio because of their mission statement in providing cutting edge, specialized, functional testing for men interested in fertility, which has a profound effect on clinical decision-making and future family building.”